Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Novo Nordisk A/S ADR Novo Alle 1 Bagsvaerd G7 2880 DNK

www.novonordisk.com Employees: 77,349 P: 45-4444-8888

Sector:

Medical

Description:

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.

Key Statistics

Overview:

Market Capitalization, $K 213,694,896
Enterprise Value, $K 226,329,040
Shares Outstanding, K 4,465,000
Annual Sales, $ 42,108 M
Annual Net Income, $ 14,643 M
Last Quarter Sales, $ 11,741 M
Last Quarter Net Income, $ 3,133 M
EBIT, $ 19,514 M
EBITDA, $ 22,285 M
60-Month Beta 0.67
% of Insider Shareholders 0.07%
% of Institutional Shareholders 11.54%
Float, K 4,461,875
% Float 99.93%
Short Volume Ratio 0.39

Growth:

1-Year Return -56.02%
3-Year Return -25.75%
5-Year Return 37.65%
5-Year Revenue Growth 130.21%
5-Year Earnings Growth 166.67%
5-Year Dividend Growth 134.09%

Per-Share Information:

Most Recent Earnings 1.02 on 11/05/25
Next Earnings Date N/A
Earnings Per Share ttm 3.82
EPS Growth vs. Prev Qtr 5.15%
EPS Growth vs. Prev Year 13.33%
Annual Dividend & Yield 1.23 (2.57%)
Annual Dividend & Yield (Fwd) 0.82 (1.72%)
Most Recent Dividend 0.412 on 08/18/25
Next Ex-Dividends Date 08/18/25
Dividend Payable Date 08/26/25
Dividend Payout Ratio 32.32%
Most Recent Split 2-1 on 09/20/23

NVO Ratios

Ratio
Price/Earnings ttm 12.56
Price/Earnings forward 13.40
Price/Earnings to Growth N/A
Return-on-Equity % 73.50%
Return-on-Assets % 23.44%
Profit Margin % 34.78%
Debt/Equity 0.60
Price/Sales 5.09
Price/Cash Flow 12.30
Price/Book 8.05
Book Value/Share 5.96
Interest Coverage 18.31

NVO Dividends

Date Value
08/18/25 $0.4120
03/31/25 $0.8190
08/16/24 $0.3620
03/22/24 $0.6630
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar